DeepMed Research

ABBVIE

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 2013-01-01

Employees: -

Market Cap: $346B

Website: http://www.abbvie.com

Clinical Trials

A Pilot Clinical Study Evaluating the Effect of Parathyroid Hormone (PTH) Lowering On Erythropoietin Consumption in Calcitriol-Resistant Patients

Phase 4

Completed

Conditions: Moderate to Severe Secondary Hyperparathyroidism
Stage 5 Chronic Kidney Diseases

Interventions: Drug: Paricalcitol
Drug: Darbepoetin alfa

First Posted Date: 2012-01-10

Last Posted Date: 2021-07-30

Lead Sponsor: AbbVie (prior sponsor, Abbott)

Target Recruit Count: 65

Registration Number: NCT01506947

A Crossover Study of the Safety and Tolerability of Two Formulations of Adalimumab

Phase 2

Completed

Conditions: Rheumatoid Arthritis

Interventions: Biological: Adalimumab

First Posted Date: 2011-12-30

Last Posted Date: 2014-02-20

Lead Sponsor: AbbVie (prior sponsor, Abbott)

Target Recruit Count: 61

Registration Number: NCT01502423

Locations: 🇦🇺
Site Reference ID/Investigator# 63354, Malvern East, Australia
🇦🇺
Site Reference ID/Investigator# 63355, Maroochydore, Australia
🇦🇺
Site Reference ID/Investigator# 63353, Shenton Park, Australia

and more 4 locations

A Pharmacokinetic Study of Levodopa and Carbidopa Intestinal Gel in Subjects With Advanced Parkinson's Disease

Phase 1

Completed

Conditions: Parkinson Disease

Interventions: Drug: Levodopa-Carbidopa

First Posted Date: 2011-12-05

Last Posted Date: 2017-11-21

Lead Sponsor: AbbVie

Target Recruit Count: 19

Registration Number: NCT01484990

Study of Safety, Tolerability, Pharmacokinetics, and Efficacy of ABT-SLV187 in Subjects With Advanced Parkinson's Disease

Phase 2

Completed

Conditions: Advanced Parkinson's Disease

Interventions: Drug: ABT-SLV187
Drug: Oral Levodopa/Carbidopa

First Posted Date: 2011-11-24

Last Posted Date: 2016-04-21

Lead Sponsor: AbbVie (prior sponsor, Abbott)

Target Recruit Count: 8

Registration Number: NCT01479127

Multi-country Post-Marketing Observational Study on Maintenance of Effectiveness of Adalimumab (Humira®) in Patients With Ankylosing Spondylitis and Psoriatic Arthritis

Completed

Conditions: Ankylosing Spondylitis
Psoriatic Arthritis

First Posted Date: 2011-11-18

Last Posted Date: 2015-07-08

Lead Sponsor: AbbVie (prior sponsor, Abbott)

Target Recruit Count: 566

Registration Number: NCT01474876

An Evaluation of the Biodistribution and Imaging Characteristics of ABT-806i (111In-ABT-806) in Subjects With Advanced Solid Tumor Types

Phase 1

Completed

Conditions: Advanced Solid Tumors

Interventions: Drug: ABT-806
Drug: ABT-806i

First Posted Date: 2011-11-16

Last Posted Date: 2013-01-14

Lead Sponsor: AbbVie (prior sponsor, Abbott)

Target Recruit Count: 18

Registration Number: NCT01472003

Locations: 🇦🇺
Site Reference ID/Investigator# 52203, Heidelberg, Australia
🇦🇺
Site Reference ID/Investigator# 58242, Herston, Australia

Study of ABT-700 in Subjects With Advanced Solid Tumors

Phase 1

Completed

Conditions: Advanced Solid Tumors

Interventions: Drug: ABT-700
Drug: docetaxel
Drug: FOLFIRI
Drug: erlotinib
Drug: cetuximab

First Posted Date: 2011-11-16

Last Posted Date: 2017-11-21

Lead Sponsor: AbbVie (prior sponsor, Abbott)

Target Recruit Count: 74

Registration Number: NCT01472016

Efficacy and Safety Study of Adalimumab in Treatment of Hidradenitis Suppurativa

Phase 3

Completed

Conditions: Hidradenitis Suppurativa (HS)

Interventions: Biological: adalimumab
Biological: placebo

First Posted Date: 2011-11-09

Last Posted Date: 2021-07-07

Lead Sponsor: AbbVie (prior sponsor, Abbott)

Target Recruit Count: 307

Registration Number: NCT01468207

Efficacy and Safety Study of Adalimumab in the Treatment of Hidradenitis Suppurativa

Phase 3

Completed

Conditions: Hidradenitis Suppurativa (HS)

Interventions: Biological: placebo
Biological: adalimumab

First Posted Date: 2011-11-09

Last Posted Date: 2021-07-12

Lead Sponsor: AbbVie (prior sponsor, Abbott)

Target Recruit Count: 326

Registration Number: NCT01468233

Clinical Study of Palivizumab in Japanese Newborns, Infants and Young Children at the Age of 24 Months or Less With Immunocompromised Medical Conditions

Phase 3

Completed

Conditions: Respiratory Syncytial Virus Infection

Interventions: Drug: Palivizumab

First Posted Date: 2011-11-06

Last Posted Date: 2013-06-17

Lead Sponsor: AbbVie (prior sponsor, Abbott)

Target Recruit Count: 28

Registration Number: NCT01466062

Locations: 🇯🇵
Site Reference ID/Investigator# 56847, Hyogo, Japan
🇯🇵
Site Reference ID/Investigator# 56843, Yokohama, Japan
🇯🇵
Site Reference ID/Investigator# 56842, Tokyo, Japan

and more 3 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy